Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US and ...
Save this article to read it later. Find this story in your account’s ‘Saved for Later’ section. Now, due in large part to Team Trump’s ineptitude, the Epstein files have become the biggest ongoing ...
Want to do your taxes away from your desk? We test and rate the top mobile tax apps that let you prepare and file your return from your phone or tablet. I write about money. I’ve been reviewing tax ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results